EGFR and colorectal cancer: Table 1 presents KEGG enrichment results sorted by the average ranks of false discovery rate (FDR) and fold enrichment. As shown, “EGFR tyrosine kinase inhibitor resistance” (p = 1.8E-14), “HIF-1 signaling pathway” (p = 3.8E-15) and “Colorectal cancer” (p = 3.2E-14) were ranked as the three top pathways.